Jeffrey Tyner

23.0k total citations · 2 hit papers
238 papers, 7.1k citations indexed

About

Jeffrey Tyner is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jeffrey Tyner has authored 238 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Hematology, 109 papers in Molecular Biology and 84 papers in Genetics. Recurrent topics in Jeffrey Tyner's work include Acute Myeloid Leukemia Research (100 papers), Chronic Myeloid Leukemia Treatments (70 papers) and Chronic Lymphocytic Leukemia Research (54 papers). Jeffrey Tyner is often cited by papers focused on Acute Myeloid Leukemia Research (100 papers), Chronic Myeloid Leukemia Treatments (70 papers) and Chronic Lymphocytic Leukemia Research (54 papers). Jeffrey Tyner collaborates with scholars based in United States, India and Singapore. Jeffrey Tyner's co-authors include Brian Druker, Marc Loriaux, Julia E. Maxson, Michael W. Deininger, Christopher A. Eide, Shannon K. McWeeney, Anupriya Agarwal, Bill H. Chang, Jason Gotlib and Elie Traer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey Tyner

223 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

2010 588 citations Jeffrey Tyner, Marc Loriaux et al. Blood profile →
OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Tyner United States	46	3.3k	2.9k	2.1k	1.3k	1.3k	238	7.1k
Martin Sattler United States	55	4.3k 1.3×	3.1k 1.1×	1.5k 0.7×	1.2k 0.9×	2.4k 1.8×	151	8.6k
Justus Duyster Germany	52	3.9k 1.2×	3.5k 1.2×	2.2k 1.0×	1.5k 1.1×	2.4k 1.8×	261	9.0k
Bruno Quesnel France	47	3.5k 1.1×	3.6k 1.3×	1.9k 0.9×	1.6k 1.2×	2.6k 2.0×	202	8.1k
David A. Rizzieri United States	44	3.0k 0.9×	4.3k 1.5×	1.6k 0.7×	1.6k 1.2×	2.5k 1.9×	309	8.1k
Katherine R. Calvo United States	39	1.7k 0.5×	2.4k 0.8×	1.4k 0.7×	1.3k 1.0×	843 0.6×	141	5.1k
Philippe Martiat Belgium	38	2.0k 0.6×	1.6k 0.5×	1.4k 0.7×	932 0.7×	1.3k 1.0×	110	5.6k
Clayton A. Smith United States	35	2.7k 0.8×	2.9k 1.0×	1.1k 0.5×	748 0.6×	1.1k 0.9×	129	5.5k
Beatríz Bellosillo Spain	45	2.9k 0.9×	1.3k 0.5×	3.2k 1.5×	1.3k 1.0×	2.3k 1.7×	231	7.6k
Ghulam J. Mufti United Kingdom	55	4.0k 1.2×	7.7k 2.6×	2.9k 1.4×	2.2k 1.7×	1.8k 1.4×	268	11.2k
Ulrich Jäger Austria	45	1.8k 0.6×	2.4k 0.8×	1.2k 0.6×	1.2k 0.9×	1.7k 1.3×	172	5.7k

Countries citing papers authored by Jeffrey Tyner

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Tyner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Tyner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Tyner more than expected).

Fields of papers citing papers by Jeffrey Tyner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Tyner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Tyner. The network helps show where Jeffrey Tyner may publish in the future.

Co-authorship network of co-authors of Jeffrey Tyner

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Tyner. A scholar is included among the top collaborators of Jeffrey Tyner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Tyner. Jeffrey Tyner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coleman, Daniel J., Joseph Estabrook, Emek Demir, et al.. (2023). Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research. 21(7). 631–647. 5 indexed citations

Romine, Kyle A., et al.. (2023). Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia. Frontiers in Oncology. 13. 1192829–1192829. 1 indexed citations

Traer, Elie, et al.. (2023). Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia. Cancers. 15(14). 3589–3589. 14 indexed citations

Romine, Kyle A., Tamilla Nechiporuk, Daniel Bottomly, et al.. (2021). Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Blood Cancer Discovery. 2(5). 518–531. 22 indexed citations

Liu, Tingting, Duanchen Sun, Xiaoguang Wang, et al.. (2021). Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX- Dependent Manner. Clinical Cancer Research. 27(17). 4910–4922. 34 indexed citations

Leonard, Jessica, Yoko Kosaka, Dorian LaTocha, et al.. (2020). Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 137(7). 939–944. 17 indexed citations

Nechiporuk, Tamilla, Stephen E. Kurtz, Olga Nikolova, et al.. (2019). The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discovery. 9(7). 910–925. 222 indexed citations

Sun, Haibo, De‐Chen Lin, Qi Cao, et al.. (2017). Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. Clinical Cancer Research. 23(15). 4376–4387. 48 indexed citations

Jiang, Yuan, Anand Mayakonda, Moli Huang, et al.. (2017). Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma. Cancer Research. 77(23). 6614–6626. 77 indexed citations

10.

Zhang, Haijiao, Anna Reister Schultz, Kevin Watanabe‐Smith, et al.. (2017). Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Research. 77(16). 4258–4267. 10 indexed citations

11.

Maxson, Julia E., Melissa L. Abel, Jinhua Wang, et al.. (2016). Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. 76(1). 127–138. 26 indexed citations

12.

DeRyckere, Deborah, Alisa B. Lee‐Sherick, Amanda A. Hill, et al.. (2016). UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research. 23(6). 1481–1492. 51 indexed citations

13.

Traer, Elie, Jacqueline Martinez, Nathalie Javidi‐Sharifi, et al.. (2016). FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Research. 76(22). 6471–6482. 96 indexed citations

14.

Maxson, Julia E., Monika A. Davare, Samuel B. Luty, et al.. (2015). Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75(11). 2146–2150. 17 indexed citations

15.

Maxson, Julia E., Samuel B. Luty, Jason D. MacManiman, et al.. (2015). The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research. 22(3). 757–764. 37 indexed citations

16.

Javidi‐Sharifi, Nathalie, Elie Traer, Jacqueline Martinez, et al.. (2014). Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75(5). 880–891. 86 indexed citations

17.

Agarwal, Anupriya, Raffaella Pippa, Christopher A. Eide, et al.. (2014). Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clinical Cancer Research. 20(8). 2092–2103. 103 indexed citations

18.

O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations

19.

Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations

20.

Eide, Christopher A., Lauren T. Adrian, Jeffrey Tyner, et al.. (2011). The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Research. 71(9). 3189–3195. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact